Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000819957 | SCV000960645 | uncertain significance | Acute myeloid leukemia | 2024-04-22 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 150 of the CEBPA protein (p.Val150Phe). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. ClinVar contains an entry for this variant (Variation ID: 662342). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV000819957 | SCV005057306 | uncertain significance | Acute myeloid leukemia | 2023-11-11 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004756043 | SCV005355398 | uncertain significance | CEBPA-related disorder | 2024-08-26 | no assertion criteria provided | clinical testing | The CEBPA c.448G>T variant is predicted to result in the amino acid substitution p.Val150Phe. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. This variant has an interpretation of uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/662342/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |